Gilead Sciences (GILD) was Initiated by Berenberg to “Buy” and the brokerage firm has set the Price Target at $112. Berenberg advised their investors in a research report released on Sep 12, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Berenberg Initiated Gilead Sciences on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $112.Gilead Sciences was Upgraded by Jefferies to ” Buy” on Sep 6, 2016. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Gilead Sciences opened for trading at $78.38 and hit $78.805 on the upside on Wednesday, eventually ending the session at $78.22, with a gain of 0.44% or 0.34 points. The heightened volatility saw the trading volume jump to 8,232,697 shares. Company has a market cap of $103,224 M.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
In a different news, on Sep 8, 2016, John F Milligan (President and CEO) sold 70,000 shares at $77.74 per share price. According to the SEC, on Sep 6, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $77.82 per share price. On Aug 25, 2016, Kevin E Lofton (director) sold 3,500 shares at $81.97 per share price, according to the Form-4 filing with the securities and exchange commission.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.